Tinnitus-Pipeline Review, H1 2016

Tinnitus-Pipeline Review, H1 2016


  • Products Id :- GMDHC7742IDB
  • |
  • Pages: 65
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Tinnitus-Pipeline Review, H1 2016', provides an overview of the Tinnitus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tinnitus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Tinnitus

The report reviews pipeline therapeutics for Tinnitus by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Tinnitus therapeutics and enlists all their major and minor projects

The report assesses Tinnitus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Tinnitus

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Tinnitus

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tinnitus pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Tinnitus Overview 7

Therapeutics Development 8

Pipeline Products for Tinnitus-Overview 8

Pipeline Products for Tinnitus-Comparative Analysis 9

Tinnitus-Therapeutics under Development by Companies 10

Tinnitus-Therapeutics under Investigation by Universities/Institutes 11

Tinnitus-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Unknown Stage Products 15

Tinnitus-Products under Development by Companies 16

Tinnitus-Products under Investigation by Universities/Institutes 17

Tinnitus-Companies Involved in Therapeutics Development 18

AudioCure Pharma GmbH 18

Auris Medical Holding AG 19

Flexion Therapeutics, Inc. 20

Knopp Biosciences LLC 21

Merz Pharma GmbH & Co. KgaA 22

Otonomy, Inc. 23

SciFluor Life Sciences, LLC 24

Sound Pharmaceuticals, Inc. 25

Tinnitus-Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 34

acamprosate calcium-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

AM-102-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

AUT-3-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Drug to Activate KCNQ for Tinnitus-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

esketamine hydrochloride-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

gacyclidine SR-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

neramexane mesylate-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

SF-0034-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Small Molecules for Tinnitus-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Small Molecules to Inhibit TNF-Alpha for Tinnitus-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

SPI-1005-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

SPI-3005-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Tinnitus-Recent Pipeline Updates 52

Tinnitus-Dormant Projects 58

Tinnitus-Product Development Milestones 59

Featured News & Press Releases 59

Nov 16, 2015: Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311 59

Oct 05, 2015: Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311 59

Jul 02, 2015: Auris Medical Holding Provides Update on U.S. Intellectual Property Portfolio 59

Jun 19, 2015: SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience 60

Apr 20, 2015: Auris Medical Announces Publications Related to AM-101 in Peer-Reviewed Scientific and Medical Journals 60

Mar 13, 2015: Auris Medical Announces Recently Granted Patent in India for the Treatment of Tinnitus 61

Mar 11, 2015: Auris Medical to Host Key Opinion Leader Meeting on Tinnitus Treatments on March 13 in New York City 62

Mar 10, 2015: Auris Medical Announces Completion of Interim Analysis in Post-Acute Tinnitus Stratum of TACTT3 Trial with AM-101 62

Feb 11, 2015: Auris Medical Announces Recently Granted Patent in China for the Treatment of Tinnitus 63

Jan 14, 2015: Auris Medical Holding AG Achieves 50% Enrolment Milestone in Post-Acute Tinnitus Stratum of TACTT3 Clinical Trial 63

Appendix 64

Methodology 64

Coverage 64

Secondary Research 64

Primary Research 64

Expert Panel Validation 64

Contact Us 64

Disclaimer 65

List of Figures

Number of Products under Development for Tinnitus, H1 2016 8

Number of Products under Development for Tinnitus-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 13

Comparative Analysis by Early Stage Products, H1 2016 14

Assessment by Monotherapy Products, H1 2016 26

Number of Products by Top 10 Targets, H1 2016 27

Number of Products by Stage and Top 10 Targets, H1 2016 27

Number of Products by Top 10 Mechanism of Actions, H1 2016 29

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 29

Number of Products by Routes of Administration, H1 2016 31

Number of Products by Stage and Routes of Administration, H1 2016 31

Number of Products by Stage and Top 10 Molecule Types, H1 2016 33

List of Tables

Number of Products under Development for Tinnitus, H1 2016 8

Number of Products under Development for Tinnitus-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Late Stage Development, H1 2016 12

Comparative Analysis by Clinical Stage Development, H1 2016 13

Comparative Analysis by Early Stage Development, H1 2016 14

Comparative Analysis by Unknown Stage Development, H1 2016 15

Products under Development by Companies, H1 2016 16

Products under Investigation by Universities/Institutes, H1 2016 17

Tinnitus-Pipeline by AudioCure Pharma GmbH, H1 2016 18

Tinnitus-Pipeline by Auris Medical Holding AG, H1 2016 19

Tinnitus-Pipeline by Flexion Therapeutics, Inc., H1 2016 20

Tinnitus-Pipeline by Knopp Biosciences LLC, H1 2016 21

Tinnitus-Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016 22

Tinnitus-Pipeline by Otonomy, Inc., H1 2016 23

Tinnitus-Pipeline by SciFluor Life Sciences, LLC, H1 2016 24

Tinnitus-Pipeline by Sound Pharmaceuticals, Inc., H1 2016 25

Assessment by Monotherapy Products, H1 2016 26

Number of Products by Stage and Target, H1 2016 28

Number of Products by Stage and Mechanism of Action, H1 2016 30

Number of Products by Stage and Route of Administration, H1 2016 32

Number of Products by Stage and Molecule Type, H1 2016 33

Tinnitus Therapeutics-Recent Pipeline Updates, H1 2016 52

Tinnitus-Dormant Projects, H1 2016 58

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AudioCure Pharma GmbH Auris Medical Holding AG Flexion Therapeutics, Inc. Knopp Biosciences LLC Merz Pharma GmbH & Co. KgaA Otonomy, Inc. SciFluor Life Sciences, LLC Sound Pharmaceuticals, Inc.

Tinnitus Therapeutic Products under Development, Key Players in Tinnitus Therapeutics, Tinnitus Pipeline Overview, Tinnitus Pipeline, Tinnitus Pipeline Assessment

select a license
Single User License
USD 2000 INR 143840
Site License
USD 4000 INR 287680
Corporate User License
USD 6000 INR 431520

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com